Akcea Therapeutics (NASDAQ: AKCA) is one of 104 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Akcea Therapeutics to similar businesses based on the strength of its earnings, dividends, analyst recommendations, institutional ownership, risk, profitability and valuation.

Insider & Institutional Ownership

26.0% of Akcea Therapeutics shares are held by institutional investors. Comparatively, 44.8% of shares of all “Pharmaceuticals” companies are held by institutional investors. 11.4% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.


This table compares Akcea Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Akcea Therapeutics N/A N/A N/A
Akcea Therapeutics Competitors -2,402.65% -69.02% -7.44%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Akcea Therapeutics and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akcea Therapeutics 0 0 4 0 3.00
Akcea Therapeutics Competitors 872 3795 6777 181 2.54

Akcea Therapeutics presently has a consensus target price of $24.00, indicating a potential upside of 35.98%. As a group, “Pharmaceuticals” companies have a potential upside of 25.58%. Given Akcea Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Akcea Therapeutics is more favorable than its rivals.

Valuation and Earnings

This table compares Akcea Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Akcea Therapeutics N/A -$83.21 million -4.48
Akcea Therapeutics Competitors $8.17 billion $1.09 billion 135.90

Akcea Therapeutics’ rivals have higher revenue and earnings than Akcea Therapeutics. Akcea Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


Akcea Therapeutics beats its rivals on 6 of the 11 factors compared.

Akcea Therapeutics Company Profile

Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company’s volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company’s clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).

Receive News & Ratings for Akcea Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.